JP2017535551A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535551A5
JP2017535551A5 JP2017526138A JP2017526138A JP2017535551A5 JP 2017535551 A5 JP2017535551 A5 JP 2017535551A5 JP 2017526138 A JP2017526138 A JP 2017526138A JP 2017526138 A JP2017526138 A JP 2017526138A JP 2017535551 A5 JP2017535551 A5 JP 2017535551A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
vegf
compound
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017526138A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535551A (ja
JP6863892B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2015/050720 external-priority patent/WO2016077878A1/en
Publication of JP2017535551A publication Critical patent/JP2017535551A/ja
Publication of JP2017535551A5 publication Critical patent/JP2017535551A5/ja
Application granted granted Critical
Publication of JP6863892B2 publication Critical patent/JP6863892B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017526138A 2014-11-17 2015-11-17 脳卒中を治療又は予防する方法 Active JP6863892B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014904606A AU2014904606A0 (en) 2014-11-17 Method of treating or preventing stroke
AU2014904606 2014-11-17
PCT/AU2015/050720 WO2016077878A1 (en) 2014-11-17 2015-11-17 Method of treating or preventing stroke

Publications (3)

Publication Number Publication Date
JP2017535551A JP2017535551A (ja) 2017-11-30
JP2017535551A5 true JP2017535551A5 (https=) 2018-12-06
JP6863892B2 JP6863892B2 (ja) 2021-04-21

Family

ID=56012959

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017526138A Active JP6863892B2 (ja) 2014-11-17 2015-11-17 脳卒中を治療又は予防する方法

Country Status (12)

Country Link
US (2) US10336821B2 (https=)
EP (1) EP3220952B1 (https=)
JP (1) JP6863892B2 (https=)
KR (1) KR102560025B1 (https=)
CN (1) CN107106681B (https=)
AU (1) AU2015349610B2 (https=)
CA (1) CA2967070C (https=)
DK (1) DK3220952T3 (https=)
ES (1) ES2881303T3 (https=)
PL (1) PL3220952T3 (https=)
RU (1) RU2744909C2 (https=)
WO (1) WO2016077878A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6187777B2 (ja) 2011-06-13 2017-08-30 シーエスエル、リミテッド G−csfrに対する抗体およびその使用
US10617756B2 (en) * 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia
US20190076510A1 (en) * 2017-09-13 2019-03-14 The Regents Of The University Of Michigan Protein kinase c inhibition to extend tissue plasminogen activator treatment for ischemic disease
CA3081770A1 (en) 2017-11-29 2019-06-06 Csl Limited Method of treating or preventing ischemia-reperfusion injury
WO2019178645A1 (en) 2018-03-23 2019-09-26 Csl Limited Method of treating asthma
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
US12583929B2 (en) 2020-06-04 2026-03-24 CSL Innovation Pty Ltd Method of treating acute respiratory distress syndrome
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
KR20260036321A (ko) 2023-07-05 2026-03-16 씨에스엘 이노베이션 피티와이 엘티디 겸상적혈구병의 합병증을 치료하거나 예방하는 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232439A1 (en) 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-B expression
PL1781321T3 (pl) * 2004-08-02 2014-07-31 Zenyth Operations Pty Ltd Sposób leczenia raka zawierający antagonistę VEGF-B
KR20130108481A (ko) * 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2007254243B2 (en) 2006-05-17 2013-06-13 Ludwig Institute For Cancer Research Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
US20110318365A1 (en) 2007-09-15 2011-12-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods for treatment of degenerative disease associated with apoptosis
US20110150900A1 (en) * 2008-04-09 2011-06-23 Ludwig Institute For Cancer Research Regulation of fatty acid transporters
JP5823671B2 (ja) * 2009-07-27 2015-11-25 国立大学法人 新潟大学 免疫製剤を含む脳梗塞治療用医薬品組成物
JP6612246B2 (ja) 2013-11-28 2019-11-27 シーエスエル、リミテッド 腎症を処置する方法
US10543270B2 (en) 2013-12-18 2020-01-28 Csl Limited Methods of treating wounds in a diabetic subject

Similar Documents

Publication Publication Date Title
JP2017535551A5 (https=)
RU2017120031A (ru) Способ лечения или предотвращения инсульта
JP2019523295A5 (https=)
JP2022534020A (ja) Il-23及びtnfアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
JP2017506626A5 (https=)
US11319368B2 (en) Treatment of hepatotoxicity with IL-11 antibody
CN106170496B (zh) 针对纤连蛋白-eda的免疫球蛋白样分子
JP2017113019A5 (https=)
RU2018135371A (ru) АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
JP2019528306A5 (https=)
EP4309734A1 (en) Methods for treating cardiovascular disease
US20250075005A1 (en) Use of alpha-enolase antagonist in treating of fibrotic diseases
JP2021501138A (ja) 虚血性再灌流障害を治療するための酸化特異的エピトープの阻害
JP7675440B2 (ja) 炎症性肺疾患の予防及び/又は治療剤
TWI566780B (zh) 巨噬細胞發炎蛋白-1β(MIP-1β)抑制劑用於促進血管新生以改善組織缺血及糖尿病血管病變的用途
US20230049147A1 (en) Anti-il-36r antibodies for the treatment of a fibrotic condition
WO2016093700A2 (en) Immunoglobulin-like molecules directed against fibronectin-eda
US20250282861A1 (en) Mfap4 and treatment of fibrosis
JP7565607B2 (ja) 肺、腎臓、または肝臓の線維症疾患の処置に使用するためのpsmpアンタゴニスト
Wang et al. Emerging Role of CXCR4 in Fibrosis
AR130862A1 (es) Composiciones de anticuerpos anti-tslp y usos de las mismas
WO1999058150A1 (en) Preventives/remedies for hepatic cirrhosis
EA047713B1 (ru) Лечение гепатотоксичности
Chan CCR1-deficiency improved survival and attenuated cardiac remodeling post-myocardial infarction
RU2019129858A (ru) Методы профилактики и лечения сердечных заболеваний